Found 87 results
Author Title Type [ Year(Asc)]
Wojkowska-Mach J, Godman B, Glassman A, Kurdi A, Pilc A, Rozanska A, Skoczyński S, Wałaszek M, Bochenek T.  2018.  Antibiotic consumption and antimicrobial resistance in Poland; findings and implications. Antimicrobial Resistance & Infection Control. 7:136.
Godman B, Bucsics A, Vella_Bonanno P, Oortwijn W, Rothe CC, Ferrario A, Bosselli S, Hill A, Martin AP, Simoens S et al..  2018.  Barriers for access to new medicines: searching for the balance between rising costs and limited budgets. Frontiers in public health. 6
Joppi R, Gerardi C, Garattini S, .  2018.  A disease looking for innovative drugs: the case of pulmonary arterial hypertension. European journal of internal medicine. 55:47–51.
Szegedi M, Zelei T, Arickx F, Bucsics A, Cohn-Zanchetta E, Fürst J, Kamusheva M, Kawalec P, Petrova G, Slaby J et al..  2018.  The European challenges of funding orphan medicinal products. Orphanet journal of rare diseases. 13:184.
Eriksson I, von Euler M, Malmström RE, Godman B, Wettermark B.  2018.  Evaluation of the Swedish Early Awareness and Alert System. metabolism. 31:6.
Wale J, Bond K, Wortley S, Martin J, Godman B, Gutiérrez-Ibarluzea I.  2018.  OP105 Disinvestment Toolkit: Patients Involvement In Disinvestment Activities. International Journal of Technology Assessment in Health Care. 34:39–40.
Bojanić L, Marković-Peković V, krbić RŠ, Stojaković N, ermanović MÐ, Bojanić J, Fürst J, Kurdi AB, Godman B.  2018.  Recent initiatives in the Republic of Srpska to enhance appropriate use of antibiotics in ambulatory care; their influence and implications. Frontiers in pharmacology. 9
Bochenek T, Abilova V, Alkan A, Asanin B, Beriain Ide Miguel, Besovic Z, Bonanno PVella, Bucsics A, Davidescu M, De Weerdt E et al..  2018.  Systemic measures and legislative and organizational frameworks aimed at preventing or mitigating drug shortages in 28 European and Western Asian countries. Frontiers in pharmacology. 8:942.
Vella_Bonanno P, Ermisch M, Godman B, Martin AP, Van Den Bergh J, Bezmelnitsyna L, Bucsics A, Arickx F, Bybau A, Bochenek T et al..  2017.  Adaptive pathways: possible next steps for payers in preparation for their potential implementation. Frontiers in pharmacology. 8:497.
Eriksson I, Wettermark B, Persson M, Edström M, Godman B, Lindhé A, Malmström RE, Ramström H, von Euler M, Christensen ABergkvist.  2017.  The Early Awareness and Alert System in Sweden: History and Current Status. Frontiers in Pharmacology. 8:674.
Eriksen J, Gustafsson LL, Ateva K, Bastholm-Rahmner P, Ovesjö M-L, Jirlow M, Juhasz-Haverinen M, Lärfars G, Malmström RE, Wettermark B et al..  2017.  High adherence to the ‘Wise List’treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines. BMJ open. 7:e014345.
Ferrario A, Araja D, Bochenek T, atić TČ, Dankó D, Dimitrova M, Fürst J, Greičiuté-Kuprijanov I, Hoxha I, Jakupi A et al..  2017.  The implementation of managed entry agreements in central and eastern europe: findings and implications. PharmacoEconomics. 35:1271–1285.
Godman B, Kurdi A, Leporowski A, Morton A, Baumgärtel C, Bochenek T, Fadare J, Finlayson A, Hussein S, Khan B et al..  2017.  Initiatives to increase the prescribing of low cost generics: the case of Scotland in the international context. Medical Research Archives.
Godman B, Diogene E, Fürst J, Garuolien\.e K, Júnior AGuerra, Joppi R, Malmstrom R, Oortwijn W, Selke G, Timoney A et al..  2017.  New models are needed to optimise the management of new medicines. HTAi’s 14th Annual Meeting.
Godman B, Wild C, Haycox A.  2017.  Patent expiry and costs for anti-cancer medicines for clinical use: expiry and costs anti-cancer medicines. Generics and Biosimilars Initiative journal. :1–3.
Moorkens E, Vulto AG, Huys I, Dylst P, Godman B, Keuerleber S, Claus B, Dimitrova M, Petrova G, Sović-Brkičić L et al..  2017.  {Policies for biosimilar uptake in Europe: An overview}. PLOS ONE. 12:e0190147.
Diogene E, Fürst J, Garuoliene K, Guerra A, Joppi R, Malmstrom R, Oortwijn W, Selke G, Timoney A, Wettermark B et al..  2017.  PP022 New Models Are Needed To Optimize The Management Of New Medicines. International Journal of Technology Assessment in Health Care. 33:78–79.
Bochenek T, Abilova V, Alkan A, Asanin B, Beriain Ide Miguel, Besovic Z, Bonanno PVella, Bucsics A, Davidescu M, De Weerdt E et al..  2017.  Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries. Frontiers in pharmacology. 8:942.